Sepsis resident survival guide: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Definition== | ==Definition== | ||
'''Sepsis''' is a [[systemic inflammatory response syndrome]] (SIRS) following an infection, and it is manifested by multi-system organ dysfunction in addition to [[hypotension]] that is not readily reversible with fluid resuscitation. | |||
'''Systemic inflammatory response syndrome (SIRS)''' is the occurrence of at least two of the following criteria:<ref name="Levy-2003">{{Cite journal | last1 = Levy | first1 = MM. | last2 = Fink | first2 = MP. | last3 = Marshall | first3 = JC. | last4 = Abraham | first4 = E. | last5 = Angus | first5 = D. | last6 = Cook | first6 = D. | last7 = Cohen | first7 = J. | last8 = Opal | first8 = SM. | last9 = Vincent | first9 = JL. | title = 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. | journal = Crit Care Med | volume = 31 | issue = 4 | pages = 1250-6 | month = Apr | year = 2003 | doi = 10.1097/01.CCM.0000050454.01978.3B | PMID = 12682500 }}</ref> | |||
:* | :* Fever > 38.0°C or hypothermia < 36.0°C, | ||
:* [[Tachycardia]] > 90 beats/minute | |||
:* [[Tachypnea]] > 20 breaths/minute or PaCO<sub>2</sub> lower than 32 mm Hg. | |||
:* [[Leucocytosis]] > 12,000/mm<sup>3</sup> or [[leucopoenia]] < 4,000/mm<sup>3</sup> | |||
''' | '''Septic shock''' is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation (infusion of 30 mL/kg of [[crystalloids]]/albumin equivalent). | ||
==Diagnostic Criteria For Sepsis== | |||
(Documented/Suspected Infection plus some of the following:)<ref name="Dellinger-2013">{{Cite journal | last1 = Dellinger | first1 = RP. | last2 = Levy |first2 = MM. | last3 = Rhodes | first3 = A. | last4 = Annane | first4 = D. | last5 = Gerlach | first5 = H. | last6 = Opal | first6 = SM. | last7 = Sevransky |first7 = JE. | last8 = Sprung | first8 = CL. | last9 = Douglas | first9 = IS. | title = Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. | journal = Crit Care Med | volume = 41 | issue = 2 | pages = 580-637 | month = Feb | year = 2013 | doi = 10.1097/CCM.0b013e31827e83af | PMID = 23353941 }}</ref> | |||
: | |||
''' | :'''General variables''' | ||
::*[[ | :* Fever > 38.3°C | ||
::* | :* [[Hypothermia]] (core temperature < 36°C) | ||
:* Heart rate > 90/min–1 or > 2 Standard deviation (SD) above the normal value for age | |||
:* Tachypnea | |||
:* Altered mental status | |||
:* Edema | |||
:* Positive fluid balance ( > 20 mL/kg over 24 hr) | |||
:* Hyperglycemia (plasma glucose > 140 mg/dL or 7.7 mmol/L) in the absence of diabetes | |||
:'''Inflammatory variables''' | |||
:* Leukocytosis (WBC count > 12,000 µL–1) | |||
:* Leukopenia (WBC count < 4000 µL–1) | |||
:* Immature WBCs forms are > 10% with normal count | |||
:* Plasma [[C-reactive protein]] > 2 SD above the normal value | |||
:* Plasma [[procalcitonin]] > 2 SD above the normal value | |||
''' | :'''Hemodynamic variables''' | ||
:* Arterial hypotension after 30 ml/kg fluid bolus (Systolic blood pressure (SBP) < 90 mm Hg, mean arterial pressure (MAP) < 70 mm Hg, or an SBP decrease > 40 mm Hg in adults or < 2 SD below normal for age) | |||
''' | :'''Organ dysfunction variables''' | ||
:* Arterial [[hypoxemia]] (Pao2/Fio2 < 300) | |||
:* Acute oliguria (urine output < 0.5 mL/kg/hr for at least 2 hrs despite adequate fluid resuscitation) | |||
:* Creatinine increase > 0.5 mg/dL or 44.2 µmol/L | |||
:* Coagulation abnormalities (INR > 1.5 or aPTT > 60 Sec) | |||
:* Ileus (absent bowel sounds) | |||
:* Thrombocytopenia (platelet count < 100,000 µL–1) | |||
:* Hyperbilirubinemia (plasma total bilirubin > 4 mg/dL or 70 µmol/L) | |||
:'''Tissue perfusion variables''' | |||
:* Hyperlactatemia > 1 mmol/L | |||
:''' | :* Decreased capillary refill or mottling | ||
:* | |||
:* | |||
==Severe Sepsis== | |||
Severe sepsis refers to sepsis-induced tissue hypoperfusion or organ dysfunction with one of the following, due to infection:<ref name="Dellinger-2013">{{Cite journal | last1 = Dellinger | first1 = RP. | last2 = Levy | first2 = MM. | last3 = Rhodes | first3 = A. | last4 = Annane | first4 = D. | last5 = Gerlach |first5 = H. | last6 = Opal | first6 = SM. | last7 = Sevransky | first7 = JE. | last8 = Sprung | first8 = CL. | last9 = Douglas | first9 = IS. | title = Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. | journal = Crit Care Med | volume = 41 | issue = 2| pages = 580-637 | month = Feb | year = 2013 | doi = 10.1097/CCM.0b013e31827e83af | PMID = 23353941 }}</ref> | |||
: | <ref name="Levy-2003">{{Cite journal | last1 = Levy | first1 = MM. | last2 = Fink | first2 = MP. | last3 = Marshall | first3 = JC. | last4 = Abraham | first4 = E. | last5 = Angus | first5 = D. | last6 = Cook | first6 = D. | last7 = Cohen | first7 = J. | last8 = Opal | first8 = SM. | last9 = Vincent | first9 = JL. |title = 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. | journal = Crit Care Med | volume = 31 | issue = 4 | pages = 1250-6 | month = Apr | year = 2003 | doi = 10.1097/01.CCM.0000050454.01978.3B | PMID = 12682500 }}</ref> | ||
: | |||
: | :* Sepsis-induced hypotension - systolic blood pressure (SBP) <90 mmHg or mean arterial pressure (MAP) <70 mmHg or a SBP decrease >40 mmHg or less than two standard deviations below normal for age in the absence of other causes of hypotension | ||
:* Lactate above upper limits laboratory normal | |||
:* Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation | |||
:* [[Acute lung injury]] with Pao2/Fio2 < 250 in the absence of pneumonia as infection source | |||
:* [[Acute lung injury]] with Pao2/Fio2 < 200 in the presence of pneumonia as infection source | |||
:* [[Creatinine]] > 2.0 mg/dL (176.8 μmol/L) | |||
:* [[Bilirubin]] > 2 mg/dL (34.2 μmol/L) | |||
:* Platelet count < 100,000 μL | |||
:* [[Coagulopathy]] (international normalized ratio > 1.5) | |||
:: | |||
:: | |||
:: | |||
:* | |||
==Causes== | ==Causes== | ||
Line 75: | Line 71: | ||
===Life Threatening Causes=== | ===Life Threatening Causes=== | ||
:*Bacteremia: 95% of positive blood cultures were associated with sepsis, severe sepsis, or septic shock.<ref name="Jones-1996">{{Cite journal | last1 = Jones | first1 = GR. | last2 = Lowes | first2 = JA. | title = The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. | journal = QJM | volume = 89 | issue = 7 | pages = 515-22 | month = Jul | year = 1996 | doi = | PMID = 8759492 }}</ref>. However septic shock can occur without bacteremia "viable bacteria in the blood". In fact, septic shock is associated with culture-positive bacteremia in only 30-50% of cases.<ref name="Brun-Buisson-1995">{{Cite journal | last1 = Brun-Buisson | first1 = C. | last2 = Doyon | first2 = F. | last3 = Carlet | first3 = J. | last4 = Dellamonica | first4 = P. | last5 = Gouin | first5 = F. | last6 = Lepoutre | first6 = A. | last7 = Mercier | first7 = JC. | last8 = Offenstadt | first8 = G. |last9 = Régnier | first9 = B. | title = Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. | journal = JAMA | volume = 274 | issue = 12 | pages = 968-74 | month = Sep | year = 1995 | doi = |PMID = 7674528 }}</ref><ref name="Sands-1997">{{Cite journal | last1 = Sands | first1 = KE. | last2 = Bates | first2 = DW. | last3 = Lanken | first3 = PN. |last4 = Graman | first4 = PS. | last5 = Hibberd | first5 = PL. | last6 = Kahn | first6 = KL. | last7 = Parsonnet | first7 = J. | last8 = Panzer | first8 = R.| last9 = Orav | first9 = EJ. | title = Epidemiology of sepsis syndrome in 8 academic medical centers. | journal = JAMA | volume = 278 | issue = 3 | pages = 234-40 | month = Jul | year = 1997 | doi = | PMID = 9218672 }}</ref><ref name="Kumar-2006">{{Cite journal | last1 = Kumar | first1 = A. | last2 = Roberts |first2 = D. | last3 = Wood | first3 = KE. | last4 = Light | first4 = B. | last5 = Parrillo | first5 = JE. | last6 = Sharma | first6 = S. | last7 = Suppes |first7 = R. | last8 = Feinstein | first8 = D. | last9 = Zanotti | first9 = S. | title = Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. | journal = Crit Care Med | volume = 34 | issue = 6 | pages = 1589-96 | month = Jun |year = 2006 | doi = 10.1097/01.CCM.0000217961.75225.E9 | PMID = 16625125 }}</ref><ref name="Bernard-2001">{{Cite journal | last1 = Bernard | first1 = GR. |last2 = Vincent | first2 = JL. | last3 = Laterre | first3 = PF. | last4 = LaRosa | first4 = SP. | last5 = Dhainaut | first5 = JF. | last6 = Lopez-Rodriguez |first6 = A. | last7 = Steingrub | first7 = JS. | last8 = Garber | first8 = GE. | last9 = Helterbrand | first9 = JD. | title = Efficacy and safety of recombinant human activated protein C for severe sepsis. | journal = N Engl J Med | volume = 344 | issue = 10 | pages = 699-709 | month = Mar | year = 2001 |doi = 10.1056/NEJM200103083441001 | PMID = 11236773 }}</ref> | :*Bacteremia: 95% of positive blood cultures were associated with sepsis, severe sepsis, or septic shock.<ref name="Jones-1996">{{Cite journal | last1 = Jones| first1 = GR. | last2 = Lowes | first2 = JA. | title = The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. |journal = QJM | volume = 89 | issue = 7 | pages = 515-22 | month = Jul | year = 1996 | doi = | PMID = 8759492 }}</ref>. However septic shock can occur without bacteremia "viable bacteria in the blood". In fact, septic shock is associated with culture-positive bacteremia in only 30-50% of cases.<ref name="Brun-Buisson-1995">{{Cite journal | last1 = Brun-Buisson | first1 = C. | last2 = Doyon | first2 = F. | last3 = Carlet | first3 = J. | last4 = Dellamonica | first4 = P. | last5 = Gouin | first5 = F. | last6 = Lepoutre | first6 = A. | last7 = Mercier | first7 = JC. | last8 = Offenstadt | first8 = G. |last9 = Régnier |first9 = B. | title = Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. | journal = JAMA | volume = 274 | issue = 12 | pages = 968-74 | month = Sep | year = 1995 | doi = |PMID = 7674528}}</ref><ref name="Sands-1997">{{Cite journal | last1 = Sands | first1 = KE. | last2 = Bates | first2 = DW. | last3 = Lanken | first3 = PN. |last4 = Graman |first4 = PS. | last5 = Hibberd | first5 = PL. | last6 = Kahn | first6 = KL. | last7 = Parsonnet | first7 = J. | last8 = Panzer | first8 = R.| last9 = Orav |first9 = EJ. | title = Epidemiology of sepsis syndrome in 8 academic medical centers. | journal = JAMA | volume = 278 | issue = 3 | pages = 234-40 | month = Jul | year = 1997 | doi = | PMID = 9218672 }}</ref><ref name="Kumar-2006">{{Cite journal | last1 = Kumar | first1 = A. | last2 = Roberts |first2 = D. | last3 = Wood | first3 = KE. | last4 = Light | first4 = B. | last5 = Parrillo | first5 = JE. | last6 = Sharma | first6 = S. | last7 = Suppes |first7 = R. | last8 = Feinstein | first8 = D. | last9 = Zanotti | first9 = S. | title = Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. | journal = Crit Care Med | volume = 34 | issue = 6 | pages = 1589-96 | month = Jun |year = 2006 | doi = 10.1097/01.CCM.0000217961.75225.E9 | PMID = 16625125 }}</ref><ref name="Bernard-2001">{{Cite journal | last1 = Bernard | first1 = GR. |last2 = Vincent |first2 = JL. | last3 = Laterre | first3 = PF. | last4 = LaRosa | first4 = SP. | last5 = Dhainaut | first5 = JF. | last6 = Lopez-Rodriguez |first6 = A. | last7 = Steingrub | first7 = JS. | last8 = Garber | first8 = GE. | last9 = Helterbrand | first9 = JD. | title = Efficacy and safety of recombinant human activated protein C for severe sepsis. | journal = N Engl J Med | volume = 344 | issue = 10 | pages = 699-709 | month = Mar | year = 2001 |doi = 10.1056/NEJM200103083441001 | PMID = 11236773 }}</ref> | ||
===Common Causes=== | ===Common Causes=== | ||
:*Community acquired pneumonia: 48% develop severe sepsis.<ref name="Dremsizov-2006">{{Cite journal | last1 = Dremsizov | first1 = T. | last2 = Clermont |first2 = G. | last3 = Kellum | first3 = JA. | last4 = Kalassian | first4 = KG. | last5 = Fine | first5 = MJ. | last6 = Angus | first6 = DC. | title = Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? | journal = Chest |volume = 129 | issue = 4 | pages = 968-78 | month = Apr | year = 2006 | doi = 10.1378/chest.129.4.968 | PMID = 16608946 }}</ref> | :*Community acquired pneumonia: 48% develop severe sepsis.<ref name="Dremsizov-2006">{{Cite journal | last1 = Dremsizov | first1 = T. | last2 = Clermont|first2 = G. | last3 = Kellum | first3 = JA. | last4 = Kalassian | first4 = KG. | last5 = Fine | first5 = MJ. | last6 = Angus | first6 = DC. | title = Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? | journal = Chest|volume = 129 | issue = 4 | pages = 968-78 | month = Apr | year = 2006 | doi = 10.1378/chest.129.4.968 | PMID = 16608946 }}</ref> | ||
:*Diabetes and renal disease may explain the higher rates of infection related septic shock. | :*Diabetes and renal disease may explain the higher rates of infection related septic shock. | ||
:*Immunosuppression | :*Immunosuppression | ||
=== | ==Management== | ||
The following guidelines are based on 'Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012'.<ref name="Dellinger-2013">{{Cite journal | last1 = Dellinger | first1 = RP. | last2 = Levy | first2 = MM. | last3 = Rhodes | first3 = A. | last4 = Annane | first4 = D. | last5 = Gerlach | first5 = H. | last6 = Opal | first6 = SM. | last7 = Sevransky | first7 = JE. | last8 = Sprung | first8 = CL. | last9 = Douglas |first9 = IS. | title = Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. | journal = Crit Care Med |volume = 41 | issue = 2 | pages = 580-637 | month = Feb | year = 2013 | doi = 10.1097/CCM.0b013e31827e83af | PMID = 23353941 }}</ref> | |||
{{familytree/start}} | |||
{{familytree | | | | | | | | | A01 | | | | | | | | | | |A01=<div style="float: left; text-align: left "> ''' Characterize the symptoms:''' <br> ❑ Fever <br> ❑[[Hypothermia]] <br> ❑ Altered mental status <br> ❑ [[Mottling]] <br> ❑ [[Ileus]] <br> ❑ [[Oliguria]] </div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | B01 | | | | | | | | | | |B01=<div style="float: left; text-align: left "> '''Examine the patient:''' <br> ❑ Tachycardia <br> ❑ Tachypnea <br> ❑ Edema <br> ❑ Hyperglycemia <br> ❑ Hypotension after an initial 30 ml/Kg bolus <br> ❑ Decreased capillary refill </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | C01 | | | | | | | | | | |C01=<div style="float: left; text-align: left "> '''Order labs:''' <br> ❑ Random blood sugar (RBS) <br>❑ Complete blood count (CBC) <br> ❑ [[C-reactive protein|Plasma C reactive protein (CRP)]] <br> ❑ [[Procalcitonin|Plasma procalcitonin]] <br> ❑ Pulse oximetry<br> ❑ Urinalysis/Renal function tests <br> ❑ PT/INR <br> ❑ Liver function tests <br> ❑ Serum lactate <br> ❑ Central venous pressure (CVP) </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left "> '''Consider alternative diagnosis:''' <br> ❑ Infections <br> ❑ [[Acute pancreatitis]] <br> ❑ [[Diabetic ketoacidosis]] <br> [[Lower gastrointestinal bleeding]] <br> [[Myocardial infarction]] </div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left "> '''Initial resuscitation: Goals to achieve in first 6 hours''' <br> ❑ Central venous pressure (CVP) 8-12 mm Hg <br> ❑ Mean arterial pressure (MAP) ≥ 65 mm Hg <br> ❑ Urine output ≥ 0/5 mL/Kg/hr <br> ❑ Central venous O<sub>2</sub> sat. 70% <br> ❑ If lactate levels elevated, target is normalization </div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | F01 | | | | | | | | | | |F01=<div style="float: left; text-align: left "> '''Diagnosis:''' <br> ❑ Perform 2 sets of blood cultures (aerobic and anaerobic) atleast, before starting antibiotics <br> | |||
:# Drawn percutaneously <br> | |||
:# Drawn through each vascular access device present for > 48 hours <br> | |||
❑ Perform 1,3 beta-D-glucan assay, mannan, anti-mannan antibody assay if available <br> ❑ Perform imaging studies as appropriate to locate a source </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | G01 | | | | | | | | | | |G01=<div style="float: left; text-align: left "> '''Antimicrobial therapy:''' <br> ❑ Initiate within 1st hour of diagnosis <br> Reassess regimen daily <br> ❑ Use low procalitonin levels for prognosis <br> ❑ Usual duration of therapy 10 days <br> ❑ Longer in neutropenics, slow responders, undrainable foci, immunologically compromised </div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | H01 | | | | | | | | | | |H01=Choice of antibiotics }} | |||
{{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | }} | |||
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | }} | |||
{{familytree | I01 | | I02 | | I03 | | I04 | | I05 | | |I01='''Unknown organism''' <br> ❑ Empiric therapy with broad spectrum antbiotic with good tissue penetrance |I02= '''[[Neutropenic]] pt with severe sepsis (goal is to cover [[Acinetobacter]] & [[Pseudomonas]] spp)''' <br> ❑ Use combination empirical therapy |I03='''Severe infections + resp failure + septic shock''' <br> ❑ Extended spectrum [[Beta-lactam antibiotic|beta lactam]] and[[aminoglycoside]]/[[fluoroquinolone]] |I04= '''[[Streptococcus pneumoniae]]''' <br> ❑ [[Beta-lactam antibiotic|beta lactam]] + [[macrolide]] |I05='''Culture specific organism''' <br> ❑ Shift to appropriate anti-bacterial, antiviral or antifungal }} | |||
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | }} | |||
{{familytree | |`|-|-|-|^|-|-|-|+|-|-|-|^|-|-|-|'| | | }} | |||
{{familytree | | | | | | | | | J01 | | | | | | | | | |J01=<div style="float: left; text-align: left "> '''Remove source/foci of infection:''' <br> ❑ Use minimally invasive process <br> ❑ Source removal best done in first 12 hours <br> ❑ Remove intravascular access devices if they are a possible source | |||
---- | |||
❑ Oral [[chlorhexidine gluconate]] to reduce oral contamination as a risk factor for [[ventilator associated pneumonia]] </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | K01 | | | | | | | | | |K01=<div style="float: left; text-align: left "> Hemodynamic support <br> '''Fluid therapy:''' <br> ❑ Administer [[crystalloids]], use albumin when demand for fluids is too high <br> ❑ Use dynamic variables (change in pulse pressure, stroke volume) and static variables (arterial pressure,heart rate) to assess status | |||
---- | |||
'''[[Vasopressors]] (to achieve target MAP ≥ 65 mm Hg):''' <br> ❑ Place [[arterial line]] as soon as feasible <br> ❑ Administer [[norepinephrine]] as 1st choice drug <br> ❑ Use [[epinephrine]] - when additional agent needed <br> ❑ Use [[vasopressin]] 0.03 units/minute to raise MAP or decrease norepinephrine usage <br> ❑ Selective [[dopamine]] (absolute or relative bradycardia) and [[phenylephrine]] usage | |||
---- | |||
'''Inotropic therapy:''' <br> ❑ Trial of [[dobutamine]] infusion 20 μg/Kg if cardiac output low with elevated cardiac filling pressure </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | L01 | | | | | | | | | |L01=<div style="float: left; text-align: left "> '''Corticosteroids:''' <br> ❑ Use continuous flow IV[[hydrocortisone]] 200 mg/day if shock doesn’t improve with fluids & vasopressor <br> ❑ Taper when vasopressors no longer required </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | M01 | | | | | | | | | |M01=<div style="float: left; text-align: left "> '''Blood products:''' <br> ❑ Transfuse blood when hemoglobin < 7.0 g/dL <br> ❑ Transfuse platelets if < 10,000/mm<sup>3</sup> or < 20,000/mm<sup>3</sup> in those with high risk </div> }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | N01 | | | | | | | | | |N01=<div style="float: left; text-align: left "> '''Mechanical ventilation for sepsis induced ARDS':'''<br> ❑ Target tidal volume of 6 mL/Kg <br> ❑ Target plateau pressure ≤ 30 mm Hg <br> ❑ Use PEEP (positive end expiratory pressure) to avoid alveolar collapse<br> ❑ Raise patients bed to 30-45° <br> ❑ Attempt weaning when all foll. criteria are met: <br> | |||
:# ❑ Pt arousable | |||
:# ❑ Hemodynamics stable | |||
:# ❑ No new complications | |||
:# ❑ Low ventilatory/fiO<sub>2</sub> requirements <br> | |||
❑ Extubate when weaning successful </div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | O01 | | | | | | | | | |O01=<div style="float: left; text-align: left "> Other supportive therapy <br> '''Sedation & neuromuscular blockade:''' <br> ❑ Use minimal sedation/[[Neuromuscular-blocking drugs|neuromuscular blockade]] in mechanically ventilated patients | |||
---- | |||
'''Glucose control:''' <br> ❑ Blood glucose target value should be ≤ 180 mg/dL <br> ❑ Use insulin infusion and 1-2 hourly monitoring to achieve target | |||
---- | |||
'''Renal replaement therapy:''' <br> ❑ May be used for management of fluid balance in hemodynamically unstable patients <br> ❑ Use for septic patients with[[acute renal failure]] | |||
---- | |||
'''DVT prophylaxis:''' <br> ❑ Do pharmacoprophylaxis with [[low molecular weight heparin]] (LMWH), if no contraindications present <br> ❑ Use [[Intermittent pneumatic compression|pneumatic compression devices]] whenever possible | |||
---- | |||
'''Stress ulcer prophylaxis''' <br> ❑ Consider prophylaxis if risk factors are present | |||
---- | |||
'''Feeding:''' <br> ❑ Enteral & oral feeding preferred over total parenteral feeding (TPN) <br> ❑ Adjust calorie requirement in subsequent days, as tolerated | |||
---- | |||
'''Goals of care:''' <br> ❑ Discuss goals or care, patient aspirations and future directives with family with 72 hours of admission </div>}} | |||
{{familytree | | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree/end}} | |||
==Do's== | |||
* Patients who are suspected of being severely infected, should be routinely screened for sepsis. | |||
* Administer antimicrobial therapy within 1 hour of diagnosis of sepsis. | |||
* Delay intervention, if source/foci of infection is peri-pancreatic necrosis. | |||
== | ==Dont's== | ||
* Do not use empiric combination therapy for more than 3-5 days. | |||
* Do not use antimicrobial agents in severely inflamed patients, from a non-infectious cause. | |||
* Do not use [[hydroxyethyl starch]] for fluid therapy resuscitation of severe sepsis and septic shock. | |||
* Do not use low dose vasopressin/dopamine/phenylephrine as monotherapy. | |||
* Do not use low dose dopamine for renal protection. | |||
* Do not use [[corticosteroid]]s in the absence of shock. | |||
* Do not use [[erythropoietin]] as a specific treatment of anemia associated with sepsis. | |||
* Do not use antithrombin. | |||
* Do not use fresh frozen plasma to correct clotting abnormalities in the absence of bleeding or planned invasive procedure. | |||
* Do not use following supportive therapies as their role is not clear: | |||
: IV [[immunoglobulin]]s | |||
: IV selenium | |||
: | |||
* Do not routinely use pulmonary artery catheters. | |||
* Do not use bicarbonate therapy as prophylaxis of hypoperfusion induced [[lactic acidosis]] if pH > 7.15. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Help]] | ||
[[Category:Projects]] | |||
[[Category:Resident survival guide]] | [[Category:Resident survival guide]] | ||
[[Category:Templates]] | |||
{{ | {{WikiDoc Help Menu}} | ||
{{ | {{WikiDoc Sources}}{{familytree/start |summary=DKA}} |
Revision as of 16:00, 4 March 2014
Sepsis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Sepsis resident survival guide On the Web |
American Roentgen Ray Society Images of Sepsis resident survival guide |
Risk calculators and risk factors for Sepsis resident survival guide |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Definition
Sepsis is a systemic inflammatory response syndrome (SIRS) following an infection, and it is manifested by multi-system organ dysfunction in addition to hypotension that is not readily reversible with fluid resuscitation.
Systemic inflammatory response syndrome (SIRS) is the occurrence of at least two of the following criteria:[1]
- Fever > 38.0°C or hypothermia < 36.0°C,
- Tachycardia > 90 beats/minute
- Tachypnea > 20 breaths/minute or PaCO2 lower than 32 mm Hg.
- Leucocytosis > 12,000/mm3 or leucopoenia < 4,000/mm3
Septic shock is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation (infusion of 30 mL/kg of crystalloids/albumin equivalent).
Diagnostic Criteria For Sepsis
(Documented/Suspected Infection plus some of the following:)[2]
- General variables
- Fever > 38.3°C
- Hypothermia (core temperature < 36°C)
- Heart rate > 90/min–1 or > 2 Standard deviation (SD) above the normal value for age
- Tachypnea
- Altered mental status
- Edema
- Positive fluid balance ( > 20 mL/kg over 24 hr)
- Hyperglycemia (plasma glucose > 140 mg/dL or 7.7 mmol/L) in the absence of diabetes
- Inflammatory variables
- Leukocytosis (WBC count > 12,000 µL–1)
- Leukopenia (WBC count < 4000 µL–1)
- Immature WBCs forms are > 10% with normal count
- Plasma C-reactive protein > 2 SD above the normal value
- Plasma procalcitonin > 2 SD above the normal value
- Hemodynamic variables
- Arterial hypotension after 30 ml/kg fluid bolus (Systolic blood pressure (SBP) < 90 mm Hg, mean arterial pressure (MAP) < 70 mm Hg, or an SBP decrease > 40 mm Hg in adults or < 2 SD below normal for age)
- Organ dysfunction variables
- Arterial hypoxemia (Pao2/Fio2 < 300)
- Acute oliguria (urine output < 0.5 mL/kg/hr for at least 2 hrs despite adequate fluid resuscitation)
- Creatinine increase > 0.5 mg/dL or 44.2 µmol/L
- Coagulation abnormalities (INR > 1.5 or aPTT > 60 Sec)
- Ileus (absent bowel sounds)
- Thrombocytopenia (platelet count < 100,000 µL–1)
- Hyperbilirubinemia (plasma total bilirubin > 4 mg/dL or 70 µmol/L)
- Tissue perfusion variables
- Hyperlactatemia > 1 mmol/L
- Decreased capillary refill or mottling
Severe Sepsis
Severe sepsis refers to sepsis-induced tissue hypoperfusion or organ dysfunction with one of the following, due to infection:[2] [1]
- Sepsis-induced hypotension - systolic blood pressure (SBP) <90 mmHg or mean arterial pressure (MAP) <70 mmHg or a SBP decrease >40 mmHg or less than two standard deviations below normal for age in the absence of other causes of hypotension
- Lactate above upper limits laboratory normal
- Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
- Acute lung injury with Pao2/Fio2 < 250 in the absence of pneumonia as infection source
- Acute lung injury with Pao2/Fio2 < 200 in the presence of pneumonia as infection source
- Creatinine > 2.0 mg/dL (176.8 μmol/L)
- Bilirubin > 2 mg/dL (34.2 μmol/L)
- Platelet count < 100,000 μL
- Coagulopathy (international normalized ratio > 1.5)
Causes
Life Threatening Causes
Common Causes
- Community acquired pneumonia: 48% develop severe sepsis.[8]
- Diabetes and renal disease may explain the higher rates of infection related septic shock.
- Immunosuppression
Management
The following guidelines are based on 'Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012'.[2]
Characterize the symptoms: ❑ Fever ❑Hypothermia ❑ Altered mental status ❑ Mottling ❑ Ileus ❑ Oliguria | |||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Tachycardia ❑ Tachypnea ❑ Edema ❑ Hyperglycemia ❑ Hypotension after an initial 30 ml/Kg bolus ❑ Decreased capillary refill | |||||||||||||||||||||||||||||||||||||||||||
Order labs: ❑ Random blood sugar (RBS) ❑ Complete blood count (CBC) ❑ Plasma C reactive protein (CRP) ❑ Plasma procalcitonin ❑ Pulse oximetry ❑ Urinalysis/Renal function tests ❑ PT/INR ❑ Liver function tests ❑ Serum lactate ❑ Central venous pressure (CVP) | |||||||||||||||||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Infections ❑ Acute pancreatitis ❑ Diabetic ketoacidosis Lower gastrointestinal bleeding Myocardial infarction | |||||||||||||||||||||||||||||||||||||||||||
Initial resuscitation: Goals to achieve in first 6 hours ❑ Central venous pressure (CVP) 8-12 mm Hg ❑ Mean arterial pressure (MAP) ≥ 65 mm Hg ❑ Urine output ≥ 0/5 mL/Kg/hr ❑ Central venous O2 sat. 70% ❑ If lactate levels elevated, target is normalization | |||||||||||||||||||||||||||||||||||||||||||
Diagnosis: ❑ Perform 2 sets of blood cultures (aerobic and anaerobic) atleast, before starting antibiotics
❑ Perform imaging studies as appropriate to locate a source | |||||||||||||||||||||||||||||||||||||||||||
Antimicrobial therapy: ❑ Initiate within 1st hour of diagnosis Reassess regimen daily ❑ Use low procalitonin levels for prognosis ❑ Usual duration of therapy 10 days ❑ Longer in neutropenics, slow responders, undrainable foci, immunologically compromised | |||||||||||||||||||||||||||||||||||||||||||
Choice of antibiotics | |||||||||||||||||||||||||||||||||||||||||||
Unknown organism ❑ Empiric therapy with broad spectrum antbiotic with good tissue penetrance | Neutropenic pt with severe sepsis (goal is to cover Acinetobacter & Pseudomonas spp) ❑ Use combination empirical therapy | Severe infections + resp failure + septic shock ❑ Extended spectrum beta lactam andaminoglycoside/fluoroquinolone | Streptococcus pneumoniae ❑ beta lactam + macrolide | Culture specific organism ❑ Shift to appropriate anti-bacterial, antiviral or antifungal | |||||||||||||||||||||||||||||||||||||||
Remove source/foci of infection: ❑ Use minimally invasive process ❑ Source removal best done in first 12 hours ❑ Remove intravascular access devices if they are a possible source ❑ Oral chlorhexidine gluconate to reduce oral contamination as a risk factor for ventilator associated pneumonia | |||||||||||||||||||||||||||||||||||||||||||
Hemodynamic support Fluid therapy: ❑ Administer crystalloids, use albumin when demand for fluids is too high ❑ Use dynamic variables (change in pulse pressure, stroke volume) and static variables (arterial pressure,heart rate) to assess status Vasopressors (to achieve target MAP ≥ 65 mm Hg): Inotropic therapy: ❑ Trial of dobutamine infusion 20 μg/Kg if cardiac output low with elevated cardiac filling pressure | |||||||||||||||||||||||||||||||||||||||||||
Corticosteroids: ❑ Use continuous flow IVhydrocortisone 200 mg/day if shock doesn’t improve with fluids & vasopressor ❑ Taper when vasopressors no longer required | |||||||||||||||||||||||||||||||||||||||||||
Blood products: ❑ Transfuse blood when hemoglobin < 7.0 g/dL ❑ Transfuse platelets if < 10,000/mm3 or < 20,000/mm3 in those with high risk | |||||||||||||||||||||||||||||||||||||||||||
Mechanical ventilation for sepsis induced ARDS': ❑ Target tidal volume of 6 mL/Kg ❑ Target plateau pressure ≤ 30 mm Hg ❑ Use PEEP (positive end expiratory pressure) to avoid alveolar collapse ❑ Raise patients bed to 30-45° ❑ Attempt weaning when all foll. criteria are met:
| |||||||||||||||||||||||||||||||||||||||||||
Other supportive therapy Sedation & neuromuscular blockade: ❑ Use minimal sedation/neuromuscular blockade in mechanically ventilated patients Glucose control: Renal replaement therapy: DVT prophylaxis: Stress ulcer prophylaxis Feeding: Goals of care: ❑ Discuss goals or care, patient aspirations and future directives with family with 72 hours of admission | |||||||||||||||||||||||||||||||||||||||||||
Do's
- Patients who are suspected of being severely infected, should be routinely screened for sepsis.
- Administer antimicrobial therapy within 1 hour of diagnosis of sepsis.
- Delay intervention, if source/foci of infection is peri-pancreatic necrosis.
Dont's
- Do not use empiric combination therapy for more than 3-5 days.
- Do not use antimicrobial agents in severely inflamed patients, from a non-infectious cause.
- Do not use hydroxyethyl starch for fluid therapy resuscitation of severe sepsis and septic shock.
- Do not use low dose vasopressin/dopamine/phenylephrine as monotherapy.
- Do not use low dose dopamine for renal protection.
- Do not use corticosteroids in the absence of shock.
- Do not use erythropoietin as a specific treatment of anemia associated with sepsis.
- Do not use antithrombin.
- Do not use fresh frozen plasma to correct clotting abnormalities in the absence of bleeding or planned invasive procedure.
- Do not use following supportive therapies as their role is not clear:
- IV selenium
- Do not routinely use pulmonary artery catheters.
- Do not use bicarbonate therapy as prophylaxis of hypoperfusion induced lactic acidosis if pH > 7.15.
References
- ↑ 1.0 1.1 Levy, MM.; Fink, MP.; Marshall, JC.; Abraham, E.; Angus, D.; Cook, D.; Cohen, J.; Opal, SM.; Vincent, JL. (2003). "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference". Crit Care Med. 31 (4): 1250–6. doi:10.1097/01.CCM.0000050454.01978.3B. PMID 12682500. Unknown parameter
|month=
ignored (help) - ↑ 2.0 2.1 2.2 Dellinger, RP.; Levy, MM.; Rhodes, A.; Annane, D.; Gerlach, H.; Opal, SM.; Sevransky, JE.; Sprung, CL.; Douglas, IS. (2013). "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Crit Care Med. 41 (2): 580–637. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941. Unknown parameter
|month=
ignored (help) - ↑ Jones, GR.; Lowes, JA. (1996). "The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis". QJM. 89 (7): 515–22. PMID 8759492. Unknown parameter
|month=
ignored (help) - ↑ Brun-Buisson, C.; Doyon, F.; Carlet, J.; Dellamonica, P.; Gouin, F.; Lepoutre, A.; Mercier, JC.; Offenstadt, G.; Régnier, B. (1995). "Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis". JAMA. 274 (12): 968–74. PMID 7674528. Unknown parameter
|month=
ignored (help) - ↑ Sands, KE.; Bates, DW.; Lanken, PN.; Graman, PS.; Hibberd, PL.; Kahn, KL.; Parsonnet, J.; Panzer, R.; Orav, EJ. (1997). "Epidemiology of sepsis syndrome in 8 academic medical centers". JAMA. 278 (3): 234–40. PMID 9218672. Unknown parameter
|month=
ignored (help) - ↑ Kumar, A.; Roberts, D.; Wood, KE.; Light, B.; Parrillo, JE.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S. (2006). "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock". Crit Care Med. 34 (6): 1589–96. doi:10.1097/01.CCM.0000217961.75225.E9. PMID 16625125. Unknown parameter
|month=
ignored (help) - ↑ Bernard, GR.; Vincent, JL.; Laterre, PF.; LaRosa, SP.; Dhainaut, JF.; Lopez-Rodriguez, A.; Steingrub, JS.; Garber, GE.; Helterbrand, JD. (2001). "Efficacy and safety of recombinant human activated protein C for severe sepsis". N Engl J Med. 344 (10): 699–709. doi:10.1056/NEJM200103083441001. PMID 11236773. Unknown parameter
|month=
ignored (help) - ↑ Dremsizov, T.; Clermont, G.; Kellum, JA.; Kalassian, KG.; Fine, MJ.; Angus, DC. (2006). "Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?". Chest. 129 (4): 968–78. doi:10.1378/chest.129.4.968. PMID 16608946. Unknown parameter
|month=
ignored (help)